Screener
Crinetics Pharmaceuticals CRNX Product revenue, net — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Revenue: | ||
| Product revenue, net | $10,306 | — |
| Collaboration and license revenue | 428 | 361 |
| Total revenue | 10,734 | 361 |
| Operating expenses: | ||
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's product revenue, net — total revenue?
- Crinetics Pharmaceuticals (CRNX) reported product revenue, net — total revenue of $10.31M in Q1 2026.
- What does product revenue, net — total revenue mean?
- This metric represents the net revenue generated specifically from the sale of pharmaceutical products, excluding income from licensing, collaborations, or research grants. It serves as a primary indicator of the company's transition from a clinical-stage research entity to a commercial-stage enterprise. Tracking this figure helps investors evaluate the market adoption and commercial viability of the company's therapeutic portfolio.
Ask your AI about Crinetics Pharmaceuticals's product revenue, net — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude